Claude Hannoun

Genetic relatedness of hemagglutinins of the H1 subtype of influenza A viruses isolated from swine and birds.

The hemagglutinin (HA) gene of the influenza virus subtype H1N1 isolated from pigs and birds has been analyzed by the hybridization technique. According to the RNase protection data the HA genes of recent isolates from pigs in Northern Europe are genetically more closely related to those of isolates from birds in Europe and North America than to those of isolates from pigs in the United States, Taiwan, and Italy. Thus, two different H1N1 subtypes are circulating in the pig population. The results are consistent with the view that H1N1 viruses can be transmitted from birds to pigs and/or vice versa.

Influenza vaccination in 22 developed countries: An update to 1995

This study expands and updates through 1995 our earlier report on influenza vaccine use in 18 developed countries. Five of the six countries with high levels of vaccine use in 1992 (> or = 130 doses/1000 population) showed little change or slight declines over the subsequent 3 years. The exception was the United States, where a new federal program for vaccination reimbursement for the elderly helped to increase vaccine distribution from 144 to 239 doses/1000 population. The six countries with medium levels of vaccine use in 1992 (76-96 doses/1000 population) increased to > or = 100 doses/1000 population by 1995. Among the six low-use countries in 1992 (< or = 65 doses/1000 population), only Finland showed substantial improvement (96 doses/1000 population) in 1995. Four new countries were added to the study. In Germany, vaccine use increased to 80 doses/1000 population in 1995, but in Ireland it remained at a low level (48 doses/1000 population). In Korea, vaccine use increased from 17 to 95 doses/ 1000 population during the period 1987-1995. In Japan, very high levels of vaccine use (approximately 280 doses/1000 population) in the early 1980s were associated with vaccination programs for school children. However, vaccine use fell precipitously when these programs were discontinued, and only 2 and 8 doses/1000 population were used in 1994 and 1995, respectively. In all 22 countries, higher levels of vaccine use were associated with vaccination reimbursement programs under national or social health insurance and were not correlated with different levels of economic development. Excluding Japan, in 1995 there was still a greater than fourfold difference between the highest and lowest levels of vaccine use among the other 21 countries in the study. Given its well established clinical effectiveness and cost-effectiveness, none of these countries has yet achieved the full benefits of its programs for influenza vaccination.

Influenza vaccination in 18 developed countries, 1980-1992

Influenza continues to be an important cause of preventable morbidity and mortality. Although influenza vaccine is widely recommended for older high-risk individuals, no studies have compared its use in different countries. We gathered information on influenza vaccine distribution in 18 developed countries for the period 1980-1992. During the 1980s there was a > or = 10-fold difference in annual per capita vaccine distribution among these countries, and in 1992 the difference was still more than 7-fold. Several countries demonstrated large increases in vaccine use over the study period, some showing substantial increases in specific years. Thirteen of the 18 countries recommend influenza vaccination for all elderly persons and 11 countries provide reimbursement for vaccination through national or social health insurance. These countries tend to have higher levels of vaccine use. Historical, economic and political factors also affect vaccination practices and policies, but their relationships to differences in vaccine use between countries are not known. A better understanding of why the use of influenza vaccine varies among countries will be important if its protective benefits are to be fully realized.

The evolving history of influenza viruses and influenza vaccines

The isolation of influenza virus 80 years ago in 1933 very quickly led to the development of the first generation of live-attenuated vaccines. The first inactivated influenza vaccine was monovalent (influenza A). In 1942, a bivalent vaccine was produced after the discovery of influenza B. It was later discovered that influenza viruses mutated leading to antigenic changes. Since 1973, the WHO has issued annual recommendations for the composition of the influenza vaccine based on results from surveillance systems that identify currently circulating strains. In 1978, the first trivalent vaccine included two influenza A strains and one influenza B strain. Currently, there are two influenza B lineages circulating; in the latest WHO recommendations, it is suggested that a second B strain could be added to give a quadrivalent vaccine. The history of influenza vaccine and the associated technology shows how the vaccine has evolved to match the evolution of influenza viruses.

A new influenza surveillance system in France: The Ile-De-France “GROG”. I. Principles and methodology

The aims of influenza surveillance have changed over the years. The early detection of epidemics is essential for practical decisions on vaccine development, strategy of vaccine prophylaxis, chemoprophylaxis or chemotherapy. A new surveillance system is presented which combines the classical specific data related to the isolations, direct detection of virus as well as serological findings, with non-specific indices. The rationale for definition and elaboration of such indices is discussed: selected parameters deal with medical activity of a panel of sentinel doctors (general practitioners and pediatricians), notifications of diagnosed acute respiratory viral infections, measure of emergency doctors activity, absence from work (as seen by physicians, insurance agencies or industrial personnel), selected drug prescription and consumption, hospital admissions. The sentinel physicians also cooperate in taking samples from cases, thereby extending the field of specific surveillance since they have contact with standard cases of the disease and not only hospitalized patients. A weekly comparison of time variations of specific and non-specific indices should permit a reliable evaluation of the epidemic situation and therefore be of great help for practical decisions. The system has operated since 1984, and the initial hypothesis of the sensitivity of some of the indices has already been verified.

Studies on Lumbo virus replication: I. RNA-dependent RNA polymerase associated with virions

Abstract Purified Lumbo virus contains an enzyme that catalyzes the incorporation of ribonucleotides into RNA. Optimal conditions for the polymerase activity require the presence of Nonidet P-40, both Mg 2+ and Mn 2+ cations and all four ribonucleotides. The optimal temperature is 38.8°. Lumbo virus polymerase products anneal specifically to virion RNA. Sedimentation of RNA reaction products reveals four components: 28, 24, and 12 S RNA species with properties of double-stranded molecules and a 4 S component that appears as single-stranded RNA.

Bunyaviruses and Bunyaviridae

A new family is described, the Bunyaviridae, which contains a single genus, Bunyavirus. The main characteristics of the family are as follows: single-stranded RNA, total molecular weight about 7 X 10(6) daltons, probably in three segments. Virions spherical, enveloped particles 90-100 nm in diameter. Envelope contains at least one virus-specified glycopeptide. Develop in the cytoplasm, mature by budding into smooth-surfaced vesicles in the Golgi region or nearby. Internal ribonucleoprotein composed of long strands 2-2.5 nm broad. There are at least 150 members, 87 serologically related bunyaviruses and other probable bunyaviruses.

Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients.

The clinical reaction and the immunological response to influenza virus vaccine were studied in 43 B-cell chronic lymphocytic leukaemia patients. The Vaxigrip vaccine was administered containing the antigens A/Ghizhou/54/89, A/Singapore/6/86, and B/Yamagata/16/88. The side-effects observed were minimal and well tolerated. Antibody production with titres > 1:20 on day 15 was observed at least for one antigen in 35 patients (81%). In 23 of them (63%) this response was retained on days 30 and 60. Patients with IgG levels (< 700 mg/dl) responded less well as compared to those having normal IgG levels (> 700 mg/dl).

Three-Segment RNA Genome of Lumbo Virus (Bunyavirus)

The sedimentation analysis and polyacrylamide gel electrophoresis of RNA extracted from Lumbo and Tahyna viruses, which belong to the California group of the Bunyamwera supergroup of arboviruses, demo

Influenza C virus infection in France

Little is known of the epidemiology of influenza C virus infections in western Europe and of the exact role of this agent in acute viral respiratory infections. Several tests may be used for detecting antibodies against this agent but the significance of their respective results is not clear. A total of 301 samples of serum was collected from persons aged from 4 months to 88 years living in France in 1988. The samples were tested for the presence of antibodies to influenza C virus by haemagglutination-inhibition (HI) tests and ELISA. The specificity of the results was checked by immunoblotting and by antibody absorption with staphylococcal protein A. Significant HI activity was found in 61% of the 301 samples tested, titres ranging from 20-320; 70% were positive by ELISA with titres ranging from 500 to 32,000. The population tested was divided into four age groups: 0-15 years; 16-30 years; 31-50 years and 51-88 years. The highest rates for positive samples were found in the 16-30 year group (76 and 79% by HI tests and ELISA respectively) as well as significant HI and ELISA geometric mean titres. Positive samples were less common in young children (46 and 50% by HI tests and ELISA respectively) and in the oldest group (44 and 54% respectively). The 31-50 years age group formed an intermediate class. The high prevalence of antibody as well as the significant titres indicate intense circulation of influenza C virus, especially among young adults.